
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GXM865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.
A Roadmap for Modern RCC Care: Navigating Personalized Treatment Selection and Sequencing
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, and Exelixis, Inc.
Disclosure information is available at the beginning of the video presentation.
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GXM865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.
A Roadmap for Modern RCC Care: Navigating Personalized Treatment Selection and Sequencing
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, and Exelixis, Inc.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
317 Listeners
42 Listeners
2 Listeners
110 Listeners
2 Listeners
480 Listeners
54 Listeners
43 Listeners
21 Listeners
321 Listeners
54 Listeners
9 Listeners
166 Listeners
36 Listeners